These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 35582027)

  • 1. Liposome co-encapsulation of anti-cancer agents for pharmacological optimization of nanomedicine-based combination chemotherapy.
    Gabizon A; Ohana P; Amitay Y; Gorin J; Tzemach D; Mak L; Shmeeda H
    Cancer Drug Resist; 2021; 4(2):463-484. PubMed ID: 35582027
    [No Abstract]   [Full Text] [Related]  

  • 2. Coencapsulation of alendronate and doxorubicin in pegylated liposomes: a novel formulation for chemoimmunotherapy of cancer.
    Shmeeda H; Amitay Y; Gorin J; Tzemach D; Mak L; Stern ST; Barenholz Y; Gabizon A
    J Drug Target; 2016 Nov; 24(9):878-889. PubMed ID: 27187807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic Studies of a Prodrug of Mitomycin C in Pegylated Liposomes (Promitil(®)): High Stability in Plasma and Rapid Thiolytic Prodrug Activation in Tissues.
    Amitay Y; Shmeeda H; Patil Y; Gorin J; Tzemach D; Mak L; Ohana P; Gabizon A
    Pharm Res; 2016 Mar; 33(3):686-700. PubMed ID: 26572644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.
    Gabizon AA; Tzemach D; Horowitz AT; Shmeeda H; Yeh J; Zalipsky S
    Clin Cancer Res; 2006 Mar; 12(6):1913-20. PubMed ID: 16551877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Promitil®, a lipidic prodrug of mitomycin c in PEGylated liposomes: From bench to bedside.
    Gabizon A; Shmeeda H; Tahover E; Kornev G; Patil Y; Amitay Y; Ohana P; Sapir E; Zalipsky S
    Adv Drug Deliv Rev; 2020; 154-155():13-26. PubMed ID: 32777239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harnessing Nanomedicine to Potentiate the Chemo-Immunotherapeutic Effects of Doxorubicin and Alendronate Co-Encapsulated in Pegylated Liposomes.
    Gabizon A; Shmeeda H; Draper B; Parente-Pereira A; Maher J; Carrascal-Miniño A; de Rosales RTM; La-Beck NM
    Pharmaceutics; 2023 Nov; 15(11):. PubMed ID: 38004584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effects of free doxorubicin, liposome encapsulated doxorubicin and liposome co-encapsulated alendronate and doxorubicin (PLAD) on the tumor immunologic milieu in a mouse fibrosarcoma model.
    Islam MR; Patel J; Back PI; Shmeeda H; Adamsky K; Yang H; Alvarez C; Gabizon AA; La-Beck NM
    Nanotheranostics; 2022; 6(4):451-464. PubMed ID: 36105861
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models.
    Gabizon A; Amitay Y; Tzemach D; Gorin J; Shmeeda H; Zalipsky S
    J Control Release; 2012 Jun; 160(2):245-53. PubMed ID: 22134116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Pegylated Liposomal Mitomycin C Lipid-Based Prodrug (Promitil) by High Sensitivity Differential Scanning Calorimetry and Cryogenic Transmission Electron Microscopy.
    Wei X; Patil Y; Ohana P; Amitay Y; Shmeeda H; Gabizon A; Barenholz Y
    Mol Pharm; 2017 Dec; 14(12):4339-4345. PubMed ID: 28045540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity.
    Patil Y; Amitay Y; Ohana P; Shmeeda H; Gabizon A
    J Control Release; 2016 Mar; 225():87-95. PubMed ID: 26809007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients.
    Gabizon AA; Tahover E; Golan T; Geva R; Perets R; Amitay Y; Shmeeda H; Ohana P
    Invest New Drugs; 2020 Oct; 38(5):1411-1420. PubMed ID: 31955309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual-effect liposomes encapsulated with doxorubicin and chlorin e6 augment the therapeutic effect of tumor treatment.
    Peng PC; Hong RL; Tsai YJ; Li PT; Tsai T; Chen CT
    Lasers Surg Med; 2015 Jan; 47(1):77-87. PubMed ID: 25559348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Preclinical and Clinical Progress in Liposomal Doxorubicin.
    Aloss K; Hamar P
    Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs.
    Li X; Widjaya AS; Liu J; Liu X; Long Z; Jiang Y
    Acta Biomater; 2020 Apr; 106():301-313. PubMed ID: 32081779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
    Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
    J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remote loading paclitaxel-doxorubicin prodrug into liposomes for cancer combination therapy.
    Yu J; Wang Y; Zhou S; Li J; Wang J; Chi D; Wang X; Lin G; He Z; Wang Y
    Acta Pharm Sin B; 2020 Sep; 10(9):1730-1740. PubMed ID: 33088692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Long-circulating DOX Liposome: Formulation and Pharmacokinetics Studies.
    Xiao P; Zhao J; Huang Y; Jin R; Tang Z; Wang P; Song X; Zhu H; Yang Z; Yu N
    Pharm Nanotechnol; 2020; 8(5):391-398. PubMed ID: 32787769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance.
    Bajelan E; Haeri A; Vali AM; Ostad SN; Dadashzadeh S
    J Pharm Pharm Sci; 2012; 15(4):568-82. PubMed ID: 23106959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a Mesoporous Silica Nanoparticle Formulation Loaded with Mitomycin C Lipidic Prodrug (MLP) and In Vitro Comparison with a Clinical-Stage Liposomal Formulation of MLP.
    Manzano M; Gabizón A; Vallet-Regí M
    Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.